One of the key constraints in the MIS-C EAP has been awareness from other practitioners and hospitals in the peds space. MIS-C is rare, and even rarer that someone treating MIs-C is aware of Ryoncil.
in order for the EAP to progress to a trial, it is likely to require more patients.
this publication should help increase its awareness and generate more patients for the EAP.
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-40
-
- There are more pages in this discussion • 384 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
0.000(0.00%) |
Mkt cap ! $1.318B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.20 | $1.15 | $2.999M | 2.569M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 14285 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 41494 | 14 |
View Market Depth
| Last trade - 14.17pm 16/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |